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Abstract
Vertical transmission accounts for the majority of pediatric cases of hepatitis C viral (HCV) infection. In contrast to the adult
population who develop persistent viremia in ,80% of cases following exposure, the rate of mother-to-child transmission
(2–6%) is strikingly low. Protection from vertical transmission likely requires the coordination of multiple components of the
immune system. Placenta and decidua provide a direct connection between mother and infant. We hypothesized that
innate immune responses would differ across the three compartments (decidua, placenta and cord blood) and that hepatitis
C exposure would modify innate immunity in these tissues. The study was comprised of HCV-infected and healthy control
mother and infant pairs from whom cord blood, placenta and decidua were collected with isolation of mononuclear cells.
Multiparameter flow cytometry was performed to assess the phenotype, intracellular cytokine production and cytotoxicity
of the cells. In keeping with a model where the maternal-fetal interface provides antiviral protection, we found a gradient in
proportional frequencies of NKT and cd-T cells being higher in placenta than cord blood. Cytotoxicity of NK and NKT cells
was enhanced in placenta and placental NKT cytotoxicity was further increased by HCV infection. HCV exposure had
multiple effects on innate cells including a decrease in activation markers (CD69, TRAIL and NKp44) on NK cells and a
decrease in plasmacytoid dendritic cells in both placenta and cord blood of exposed infants. In summary, the placenta
represents an active innate immunological organ that provides antiviral protection against HCV transmission in the majority
of cases; the increased incidence in preterm labor previously described in HCV-seropositive mothers may be related to
enhanced cytotoxicity of NKT cells.
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Introduction
Hepatitis C virus (HCV) is the most common blood borne
infection in the United States (US), with an overall prevalence of
1.8% [1] that varies according to racial and ethnic groups. The
most striking clinical features of infection with HCV are its
extraordinarily high propensity to develop persistent viremia
(,80%) [2], and the high proportion of patients who develop long-
term complications including cirrhosis and liver failure [3,4].
Approximately 1% of pregnant women have HCV infection [5,6],
corresponding to 40,000 births annually in the United States. With
vertical transmission rates between 2–6% in women without HIV
co-infection, vertical transmission accounts for the vast majority of
pediatric HCV cases [7]. In light of the high rate of chronic
infection developed in the non-pregnant state and the significant
rate (15–35%) in HIV, the remarkably low rate of HCV infection
following exposure in utero and at delivery, warrants further study
[8,9]. Protection from vertical transmission of HCV likely requires
coordination of multiple components of the immune response
including cell migration for surveillance and recognition of
invading microorganisms [10]. Although the precise mechanisms
as they pertain to HCV are still unclear, it is known that during
normal pregnancy, the human decidua contains a high number of
immune cells, including macrophages, T cells, and natural killer
(NK) cells [10]. Clearly, the placental immune system represents
an active immunological organ that functions critically as a
regulator between the mother and the fetus and is capable of
responding to pathogens [10]. Moreover, a placental infection that
elicits the production of inflammatory cytokines such as IFN-c and
TNF-a could activate the maternal immune system, leading to
placental damage and preterm labor [10]. In this regard, infection
with HCV is a newly identified independent risk factor for preterm
delivery, perinatal mortality, intrauterine growth restriction, and
other complications [11–13].
The placenta provides the direct connection to maternal
decidua and is separated from maternal blood supply by only
one to three cells [14]. Despite this close connection, placental
tissue from term infants has not been characterized with respect to
immune composition or function. In contrast, decidua has been
well characterized in association with fertility and fetal loss with
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losses [15–17]. Notably, the decidual NK cell population consists
of more CD56
bright than CD56
dim, although the former popula-
tion has been shown to decline during each trimester [18].
Functional evaluation has not shown decidua cytotoxicity to be
elevated, despite an increase in activation markers and cytokine
production [19,20]. Cord blood from term infants has also been
well-characterized in both immune composition and function due
to the use of cord blood stem cells for bone marrow transplant
[21,22]. It is known that cord blood NK cells have decreased
cytokine production compared to peripheral blood [22,23].
Recognizing that pregnancy represents a unique immune
condition and the apparent paradox of the low rate of HCV fetal
transmission (compared to adults with acute infection), we
hypothesized that the innate immune profiles would be different
in placenta, decidua and cord blood and that HCV infection
would modulate innate immunity at these sites. We thus undertook
the first prospective study of the immune function of these
components in pregnant women with chronic HCV infection and
their infants.
Results
Study population
The study population was comprised of 12 treatment naı ¨ve HCV
dyads (HCV-seropositive women and their infants) and 16 healthy
pregnant non-HCV-seropositive control dyads. The populations
did not differ significantly in maternal age, race/ethnicity, infant
sex, infant gestational age or infant weight (p.0.17). The HCV
dyad mothers had a median age of 30.5 years (20–45 years), 42%
were Caucasian and 42% Hispanic. The infants in the HCV dyad
group had a median gestational age of 39+3 weeks with a median
birth weight of 3255 grams (range 1765–4560 grams). The control
group was similar with mothers having a median age of 26 years
(19–35 years), 31% were Caucasian and 56% Hispanic. Control
infants had a median gestational age of 39+2 weeks with a median
birth weight of 3440 grams (range 3100–4455 grams). The infants
were equally divided between males and females in both the HCV
and control groups. All HCV-infected mothers with identifiable
virus (n=8) were genotype 1a. Maternal viral loads measured the
day of delivery are shown in Table 1.
Direct ex vivo lymphocyte composition of placenta
Fetal placental tissue has not previously been characterized with
respect to overall lymphocyte composition, and information on the
immune composition of term maternal decidual tissue is sparse.
The innate immune system plays a central role in protection from
viral infection and is therefore the primary focus of this analysis. In
addition, this unique study cohort allowed us to study the impact
of HCV exposure on these tissue lymphocytes.
The overall lymphocyte composition of placenta is remarkably
similar to cord blood (CB) and decidua with only a few noted
differences between tissues and HCV exposure groups (Table 2).
Cord blood and maternal peripheral blood mononuclear cells
(PBMC) also demonstrate similar compositions with differences
only noted in T lymphocytes and natural killer T cells (NKTs)
(Table 2). NK cells, central to innate immunity against viral
pathogens, trend to higher levels in decidua than placenta and CB
in both controls and HCV exposed subjects. NKT (CD3
+CD56
+)
populations were found at greater frequencies within the placenta
relative to CB in control and HCV-exposed infants (p,0.008).
NKT cells increased in HCV-exposed placenta compared to
control placenta (p=0.04) (Table 2). B lymphocyte frequency
trended higher in HCV exposed infants and HCV infected
mothers. Specifically, B lymphocyte levels are higher in HCV
exposed CB compared to controls (p=0.04) with the highest levels
detected in HCV decidua (Table 2).
Dendritic cells
Dendritic cells (DC) (Lin
2DR
+BDCA
+) link the innate and
adaptive immune responses and are known to be decreased in
number and function during HCV infection [24–27]. During
pregnancy, DCs have been shown to display decreased activity in
decidua tissue as a mechanism of increased tolerance of fetal
antigens; however, DCs have not previously been evaluated in
placental tissue [28,29]. We found plasmacytoid DCs (pDC) to be
decreased in HCV-exposed infants compared to controls, both
in CB (p=0.02) and placenta (p=0.0005) (Figure 1a). No
differences were seen between CB and placenta in both controls
and HCV-exposed or between HCV-exposed and controls
subjects in the myeloid dendritic cell (mDC) population. Due to
limited numbers of available cells, DCs were not evaluated in
maternal decidua or PBMCs.
NKT and gamma delta T cells
Conventional T cells expressing clonotypic receptors (TCRs)
which recognize peptide fragments of protein antigens complexed
with MHC class I (CD8
+ cytotoxic T cells) or class II (CD4
+ helper
T cells) molecules are central players in adaptive immune
responses [13,30]. However, diverse populations of T cells express
antigen receptors of limited diversity that are not restricted by
conventional polymorphic MHC molecules [13]. These non-
conventional T cells have antigen recognition mechanisms,
cytokine profiles and responses to stimulation which differ
significantly from those of conventional T-cell populations and
some of which are shared with NK cells. Thus, they are thought to
represent important innate immune effector populations likely to
be important in the first line of defense against viral and other
pathogens [31]. The majority of non-conventional T cells also
express NK activating and inhibitory receptors and are termed
NKT cells. A small subset of NKT expresses an invariant TCR
consisting of the Va24JaQ-chain with a limited number of
b-chains (Vb8o rV b11) [32,33]. The majority of conventional T
Table 1. Maternal HCV (PCR) viral load.
Subject HCV (IU/ml) HCV Risk Factor
1 .7,692,310 Blood Transfusion
2 2,080,840 No Known
3 377,125 No Known
4 368,344 IVDU, Tattoo
5 328,662 IVDU, Tattoo
6 262,534 No Known
7 140,548 No Known
8 ,43 Blood Transfusion
9 ,43 No Known
10 ,43 Blood Transfusion
11 ,43 No Known
12 ,43 IVDU
Viral load on the day of delivery with 5 mothers demonstrating HCV Ab
positivity with HCV RNA negativity. Maternal HCV risk factors are listed with
50% having no known HCV risk factor or exposure.
IVDU = Intravenous Drug Use.
doi:10.1371/journal.pone.0012232.t001
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peripheral T cells express an alternative cd-TCR [34]. They
possess oligoclonal or invariant TCRs that recognize a wide array
of antigens including soluble non-peptide antigens and stress-
inducible proteins without the need for MHC restriction and
accumulate at sites of infection [34].
Table 2. Lymphocyte composition of cord blood, PBMC, placenta and decidua in control and HCV dyads.
T Lymphocytes
(CD3
+)
NK Cells
(CD3
-CD56
+)
CD56+ NKT
(CD3
+CD56
+)
B Lymphocytes
(CD19
+)
Macrophages
(CD14
+)
Total Dendritic
Cells
Control Cord Blood 42.0%
(20.9–79)
7.1%
(2.3–24)
0.20%
(0.1–0.7)
8.6%
(4.3–24.0)
7.9%
(3.1–21.2)
0.30%
(0.42–1.38)
HCV Cord Blood 39.7
(11.5–60)
6.9
(2.7–12.4)
0.25
(0.1–0.7)
12.5
4
(6.5–18.4)
7.2
(3.1–11.4)
0.18
(0.13–0.30)
HCV PBMC 69.5
1
(25.1–74.8)
10.3
(2.4–41.4)
2.9
(1.9–11.3)
14.5
(7.2–17.6)
11.9
(1.9–23.7)
NA
Control Placenta 43.7
(30.9–58.8)
10.7
2
(5.4–20.3)
0.70
3
(0.1–1.3)
8.3
(3.6–16.4)
5.7
(2.8–44.8)
0.22
(0.15–0.36)
HCV Placenta 45.3
(21.7–50.2)
7.1
(6.1–25.2)
1.1
(0.6–1.5)
13.5
(3.7–22.9)
5.7
(2.1–9.2)
0.12
(0.6–0.27)
Control Decidua 45.1
(18.3–57.9)
19
(13.5–33.2)
2.2
(1.0–3.0)
12.2
(10.1–33.6)
6.3
(1.7–12.7)
NA
HCV Decidua 38
(29.8–50.0)
18.9
(8.3–21.9)
1.4
(0.8–3.0)
19.3
(13.5–25.7)
6.3
(1.7–22.9)
NA
1HCV PBMC T Lymphocytes higher than HCV cord blood (p=0.02).
2Decidua NKs higher percentage than Placenta and cord blood (p,0.05).
3Placenta with higher percentage of NKTs than cord blood (p=0.005). HCV Placenta higher than Control placenta (p=0.05). Control placenta less than control decidua
(p=0.005). PBMC NKTs higher than HCV and control cord blood (p#0.03).
4Decidua B Lymphocytes higher than cord blood (p,0.05). HCV cord blood higher than control cord blood. (p,0.05).
NA = Not assessed; PBMCs were available for HCV-infected mothers only. Median and range are shown.
doi:10.1371/journal.pone.0012232.t002
Figure 1. Innate lymphocyte composition of cord blood, placenta and decidua in control and HCV dyads. Plasmacytoid dendritic cells
(pDC) were detected at similar levels in cord blood and placenta. Decreased pDCs were observed in HCV-exposed subjects compared to healthy
controls. Representative flow dot plots for cord blood are shown (a). NKT cells were elevated in decidua compared to placenta and in placenta
compared to cord blood. NKT cells are increased in HCV-exposed placenta compared to controls. Multiparameter flow analysis dot plot
demonstrating identification of NK, and NKT cell populations (b). Gamma Delta (cd) T cells are increased in placenta compared to cord blood. HCV-
exposed cord blood and placentas had increased cd T cells compared to healthy controls. Representative flow analysis plot demonstrating cd T cells
in HCV-exposed cord blood (c).
doi:10.1371/journal.pone.0012232.g001
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cells [35,36]. Spontaneous recovery from HCV infection is
associated with NKT cells that demonstrate a more activated
phenotype [36]. NKT cells are known to be increased in
decidua with a proposed role in the Th1/Th2 balance [20]. In
our study, NKT cells are higher in control decidua than in
placenta (p=0.02). Both control and HCV-exposed placenta
demonstrate higher proportional frequency of NKT than CB
(p=0.0007 and p=0.008). NKT cells were increased in HCV
exposed placenta compared to control placenta (p=0.04)
(Figure 1b). Moreover, the cytotoxicity of NKT cells (assessed
by CD107a expression) was greater in placenta than CB and
was further increased in HCV-exposed dyads (Figure 2a).
Invariant NKT cells (Va24
+Vb11
+)a r ep r e s e n ti nb o t hC Ba n d
placenta, but are less than 1% of lymphocytes in both controls
and HCV exposed.
Gamma Delta (cd) T cells comprise another innate immune
population likely to play a significant role in protection from viral
infection [37]. With a proposed role in protection from
intrauterine infection [38] during pregnancy, cd-T cells are
known to be increased in healthy term decidua compared to first
trimester decidua. As expected, we found cd-T cells are more
prevalent in placenta than CB (p=0.0005). Furthermore, HCV
exposure increased the presence of cd-T cells in both CB and
placenta (p=0.03, p=0.03) (Figure 1c).
NK cell frequency, phenotype and function
Impairment of NK cells (decreased number and function) in
acute HCV has been shown to lead to chronic HCV [3,39]. In
HCV infection, the impaired NK cells may be the result of
decreased IFN-a production by pDC resulting in impaired NK
cell and T-cell activation [40–42].
NK (CD3
2CD56
+) cells are central to the innate immune
system [42–46]. In HCV infection, NK cells in the peripheral
blood are decreased and subset frequencies are altered, e.g.,
decreased CD56
dim or the so-called effector NK cells, and
decreased cytokine production [39,44]. In addition, HCV
infection has been shown to alter NK cell surface receptors and
NK cell functionality leading to chronic infection [30]. During
pregnancy, NK cells are known to predominate maternal decidua
with a CD56
bright phenotype; however no analysis has been
completed on placental tissue [19,47]. We found that CD56
bright
NK cells were more frequent in the decidua as compared to
placenta (Supplemental Figure S1). NK cells, as a percentage of
total lymphocytes, trended higher in decidua compared to
placenta with no effect from HCV exposure (Figure S1).
As NK cells represent one of the primary anti-viral innate
immune effector population likely to be involved in protection
from HCV acquisition in the face of exposure, we tested the
hypothesis that heightened NK cell activity would be protective,
perhaps accounting for the low rate of vertical transmission from
Figure 2. NKT and NK cell cytotoxicity. NKT and NK cell cytotoxicity was measured using flow cytometric analysis of CD107a after stimulation as
described in the methods section. NKT cell cytotoxicity was increased in placenta compared to cord blood and is further amplified following HCV
exposure. Representative CD107a histogram on placenta (a). NK cell cytotoxicity is increased in placenta compared to cord blood (b). NK cell
production of IFN-c is robust in all compartments (c).
doi:10.1371/journal.pone.0012232.g002
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tion and phenotype of NK cell populations from CB and placenta
as well as term decidua. Cytotoxicity was evaluated as an
indication of NK cell function using the CD107a degranula-
tion assay. Following stimulation with PMA and Ionomycin,
placenta demonstrated greater cytotoxicity than CB (p=0.0054)
(Figure 2b). As an additional functional correlate, cytokine
production was assessed. CB is known to have decreased cytokine
production compared to peripheral blood [23]. No differences in
IFN-c (Figure 2c) or TNF-a (data not shown) production were
seen between placenta and CB in controls versus the HCV-
exposed. It is interesting to note that robust IFN-c production was
seen in both placenta and cord blood despite HCV exposure.
NK cells use a variety of cell surface receptors to control their
activation, effector functions and even proliferation [19]. Follow-
ing the identification of increased cytotoxicity in placenta, we
evaluated the phenotype of the NK cells to identify any markers of
increased activation or decreased inhibition in this population.
The phenotype of NK cells was evaluated with particular attention
to activating receptors CD69, TRAIL and NKp44 (Figure 3 and
supplemental Table S1). In addition NKG2A, NKG2C,
NKG2D, CD158a, CD158b, NKp46, NKp30 and CD161 were
also assessed (supplemental Table S2).
CD69 is an early activation marker expressed on a number of
cell types. In HCV infection, CD69 on peripheral NK cells
(CD56
dim subset) has been shown to correlate with serum ALT as
surrogate marker of liver necroinflammation and its expression on
the CD56
bright subset correlated with serum HCV RNA levels
[48]. In pregnancy, CD69
+ NK cells have previously been shown
to be elevated in decidua compared to maternal peripheral blood
[46]. In our current study, we found higher proportions of CD69
+
NK cells in both control and HCV-exposed placenta than in CB
(p=0.02 and p=0.003) and compared to HCV decidua (p=0.04)
(Figure 3a). In contrast to the finding that the frequency of
CD69
+ NK cells in the peripheral blood does not differ between
normal controls and HCV-infected patients [48], we found
decreased numbers of CD69
+ NK cells in CB, placenta, and
maternal decidua exposed to HCV (Figure 3a). This pattern was
consistent when examining the CD56
bright and CD56
dim popula-
tions (data not shown).
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), is a cytotoxicity receptor and another activation marker
found on NK cells [49,50]. TRAIL has been described to be
increased in chronic HCV [51]. TRAIL has not been evaluated on
placenta. In our dyads, TRAIL was lower in NK cells of CB and
placenta in the HCV exposed infant group (p=0.002 and
p=0.0005) and lower in decidua of HCV infected women
(p=0.02). Additionally, TRAIL was higher in placenta than in
CB and decidua of controls (p=0.05 and p=0.05) (Figure 3b).
Dysregulated expression of natural cytotoxicity receptors (NCR;
e.g., NKp30, NKp44, and NKp46) in HCV infection have been
described by a number of groups [52]. NKp44 mediates activation
of NK cells and is increased in peripheral blood of adults who clear
HCV infection [52]. During pregnancy, decidua NK cells express
NKp44 with a strong correlation with cytokine production and
cytotoxicity [53]. In contrast, maternal peripheral blood NK cells
are devoid of NKp44 [53]. In our study, NKp44 is identified at
lower frequency in HCV-exposed CB and placenta (p=0.003 and
Figure 3. NK cell surface receptor expression. Placenta and decidua NK cells express elevated CD69 compared to cord blood. HCV exposure
results in decreased NK cell CD69 expression in all tissues. Representative plots of CD69 expression on cord blood are shown (a). Placenta NK cells
have increased TRAIL compared to cord blood and decidua. TRAIL is decreased in HCV exposure in all tissues (b). NKp44 expression trends higher in
placenta NK cells compared to decidua. NKp44 expressing NK cells are decreased on HCV exposure. Representative multiparameter flow analysis of
HCV-exposed and control cord blood NKp44 expression on NK cells is shown (c).
doi:10.1371/journal.pone.0012232.g003
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than in control placenta (Figure 3c). No consistent differences
were seen in the relative expression of NKG2A, NKG2C,
NKG2D, CD158a, CD158b, NKp46, NKp30 and CD161
(Table S2). Maternal PBMCs were also compared with
differences only in CD158b (Table S2).
Discussion
Early inhibition of innate immunity contributes to the
development of persistence in HCV infection [54]. In order to
define the role placental immune function plays in protection from
vertical transmission of HCV infection, we performed the first
thorough characterization of innate cells on term placenta paired
with CB and decidua using multiparameter flow cytometry. The
principal findings of this study can be summarized as follows: 1)
the overall lymphocyte composition of placenta is remarkably
similar to CB and decidua, although NK and NKT cells are found
at greater frequencies within decidua than placenta or CB; 2)
plasmacytoid DCs are decreased in the CB and placenta of HCV-
exposed infants; 3) NK cells demonstrated greater activation
(CD69-positivity) in the placenta than in decidua or cord blood; 4)
HCV exposure increases the proportion of NKT cells and cd-T
cells in the placenta; 5) HCV infection leads to decreased numbers
of CD69
+ NK cells within the three compartments (maternal
decidua, placenta, and CB), as well as lower expression of TRAIL
and NKp44, also involved in activation; 6) robust IFN-c
production by NK cells is detectable in all three compartments
and NK cytotoxicity is greater in placenta than CB. Our analyses
of placental lymphocyte composition and phenotype support the
concept that the placenta and decidua protect the infant from viral
infiltration.
The differences in innate immune composition include
increased NKT cells in placenta compared to cord blood, in
keeping with previous studies documenting increased NKT cells in
maternal decidua compared to maternal peripheral blood [20]. It
has been proposed that the NKT cells play a significant role in
determining the Th1/Th2 balance in decidua and it is likely they
have a similar function in placenta [20]. The ability of NKT cells
to quickly produce cytokines and therefore stimulate the innate
immune response could explain their increased presence in
placenta and decidua tissue. In addition to increased NKT cells,
cd-T cells are increased in placenta compared to CB. This again
parallels the increases seen in decidua [38]. Further, our analysis
supported the previous findings of elevated NK (CD3
2CD56
+)
cells in the decidua [19], [47]. It is interesting to note the increase
is not also seen in placenta tissue. While the control placenta NK
cells are not increased compared to CB, they do demonstrate a
more activated phenotype with elevated NKG2C, CD69 and
TRAIL (Figure 3 and Table S2). More importantly, the
cytotoxicity of placenta is higher than CB. Taken together, these
data support a conceptual paradigm with a relative gradient of
NK, NKT, and cd-T cells to maximize antiviral protection for the
infant.
HCV has been shown to dysregulate a number of components
of the host immune response, but its effect on the placental-fetal
microenvironment had not been previously characterized. Circu-
lating pDC have been shown to demonstrate diminished IFN-a
production, potentially impairing T-cell and NK-cell activation
[40,41]. In keeping with these studies in adult peripheral blood, we
found that pDC were decreased in number in both CB and
placenta in HCV-exposed infants.
NKT and cd-T cells are non-conventional T cells that likely
provide an important first line of defense against infectious
pathogens. NKT cells have been shown to be important for
clearance of HCV in the acute setting [30] and a decrease in
intrahepatic NKTs has been associated with more severe
pathology in chronic HCV infection [35]. cd-T cells are part of
the innate immune response and are widely distributed in
peripheral blood and epithelial surfaces of the skin, lung, and
reproductive tract and gut. cd-T cells are known to be important
in the initial viral control of Herpes Simplex Virus, Varicella, and
West Nile virus (a flavivirus like HCV) in mouse models
[35,54,55]. The fact there is enrichment of NKT and cd-T cells
in placenta (relative to CB), and this was increased further in
HCV-exposed dyads might provide an explanation for the low
rate of HCV vertical transmission.
HCV infection has been shown to alter NK cell surface
receptors and NK cell functionality leading to chronic infection
[30]. We found that HCV infection decreased the relative
expression of activation markers CD69, TRAIL and NKp44 in
decidua, placenta and CB. Despite these phenotypic changes,
cytokine production by NK cells remained robust and NKT
cytotoxicity was increased in HCV infection. These results
represent a potential mechanism by which the placenta prevents
vertical transmission during pregnancy, and because infection
elicits NKT cytotoxicity, a mechanism that may contribute to the
observed increase in preterm labor in HCV infection [10]. Of the
16 mothers identified for the study, 3 (18%) had premature
delivery resulting in two fetal losses and one 24 week infant.
In summary, this study identifies novel data related to the
differential frequency and phenotype of innate immune cells in
paired placental-cord blood samples and provides the first formal
demonstration that HCV affects the immunobiology of the
maternal-fetal interface. Work is ongoing to define how innate
immune responses shape adaptive immune responses and protect
against vertical transmission.
Materials and Methods
Ethics Statement
The study protocol was approved by the Institutional Review
Boards at the University of Colorado and Denver Health Medical
Centre. Both written and oral consent was obtained before
samples were collected.
Study Population
The study group was comprised of HCV exposed (n=12) and
healthy control (n=16) mother infant pairs recruited from two
sites. All HCV infected mothers were HCV antibody positive prior
to enrollment with no treatment for HCV prior to or during
pregnancy. The study protocol was approved by the appropriate
institutional review board. Informed consent was obtained from
each subject.
Sample preparation and storage
Placental tissue (average 100 grams) was collected immediately
following delivery. The maternal basal plate (decidua) was
manually dissected from the fetal placental tissue. After separation
the tissue was mechanically disrupted and enzymatically digested
with collagenase 1A (Sigma Aldrich, St Louis, MO) for 60 minutes
on a rocker at 37uC. Placental and decidual mononuclear cells
were collected by Ficoll (Amersham Biosciences, Piscataway, NJ)
density gradient centrifugation. The mean placental sample
yielded 180 million mononuclear cells. Isolated mononuclear cells
were then cryopreserved (20% dimethyl sulfoxide in fetal bovine
serum) for subsequent analysis. Cord blood (80–125 ml) was
collected at the time of delivery. Mononuclear cells from cord
Immunity in HCV+ Pregnancy
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as above with an average yield of 120 million mononuclear cells.
Cell viability was confirmed by trypan blue staining. Dead cells
were excluded following thawing utilizing appropriate forward and
side scatter selection on flow cytometry, per the laboratory
standard protocol.
Flow cytometric analysis
Multiparameter flow cytometry was performed using a BD
FACSCanto II instrument (BD Biosciences, San Jose, CA)
compensated with single fluorochromes and analyzed using
FACSDiva software (BD Biosciences).
Cell surface Staining and antibodies
Fluorochrome-labeled monoclonal antibodies (MAb) specific for
TCR ab/cd, CD3, CD4, CD8, CD14, CD19, CD56, CD158a,
CD161, HLA-DR, CD69, CD45RA, Lin, NKp46 and NKp30,
were purchased from BD Biosciences (San Jose, CA). Anti-
TRAIL, and anti-NKG2A/C/D antibodies were supplied by
R&D Systems (Minneapolis, MN) and anti-Vb11 by Beckman
Coulter (Brea, CA). Anti-Va24 was obtained from Immunotech
(Prague, Czech Republic), CD158b and anti-BDCA-2 (pDCs),
BDCA-1 (mDCs) MAbs from Miltenyi (Auburn, CA). Thawed
fetal cord blood, maternal PBMC from HCV-infected mothers,
fetal placental and maternal decidual mononuclear cells were
stained for cell surface antigen expression at 4uC in the dark for
30 min, washed twice in 2 ml phosphate-buffered saline contain-
ing 1% bovine serum albumin and 0.01% sodium azide
(fluorescence-activated cell sorter wash), and subsequently fixed
in 200 ml of stabilizing fixative (BD). Isotype-matched control
antibodies were used to determine background levels of staining.
Cytokines/Intracellular Staining
Cytokine production by cord blood mononuclear cells and
placental mononuclear cells was analyzed after a 6 hour
stimulation with PMA (10 ng/ml, Sigma-Aldrich) and Ionomycin
(1 ug/ml, Sigma-Aldrich) at 37uC. Golgi Stop solution (BD
Bioscience, San Jose, CA) was added to each sample. Intracellular
cytokine staining (ICS) was carried out using Caltag solutions A
and B (Fix and Perm solutions) according to the manufacturer’s
instructions (Caltag, Burlingame, CA). Anti- TNF-a and IFN-c
antibodies were purchased from BD Biosciences.
Degranulation Assay
CD107a (LAMP) degranulation assay was performed as a well
accepted indirect measure of cytotoxicity. Cord blood and
placental mononuclear cells were stimulated, as above (PMA),
for 1 hour and then incubated for 5 hours with GolgiStop in the
presence of anti-CD107a-PerCP antibody from BD Biosciences
(San Jose, CA). Degranulation was determined by flow cytometric
analysis of increased CD107a expression on gated NK cell
populations (CD3
2CD56
+). Cells cultured under the same
conditions in absence of stimulation served as controls.
Statistical analyses
Results are expressed as median (range). Mann-Whitney U test
or Wilcoxon Matched Pairs test were used to compare differences
between patient groups as appropriate with a significance level of
0.05. Comparisons were made between the physiologic pairs of
cord blood and placenta and, decidua and placenta to minimize
comparisons. No adjustment for multiple comparisons was used as
this was an exploratory study aimed at hypothesis generation.
Decidua and cord blood were only compared for NK cell
percentages given the significant existing data on decidua. Prism 5
by Graphpad (San Diego, CA) statistical and graphing package
was used.
Supporting Information
Figure S1 NK cell and CD56
bright NK cells in placenta and
decidua. NK cells trend higher in decidua compared to placenta
(a). CD56
bright NK cells trend higher in control decidua compared
to placenta (b).
Found at: doi:10.1371/journal.pone.0012232.s001 (0.67 MB TIF)
Table S1 Innate immune cell lines and cell surface markers of
interest (median and range).
Found at: doi:10.1371/journal.pone.0012232.s002 (0.04 MB
DOC)
Table S2 Stimulatory and inhibitory NK cell surface markers
Percent of lymphocytes (median and range). *NKG2C is higher in
control placenta compared to cord blood. (p=0.01) ‘NKG2D is
lower in control placenta compared to cord blood (p=0.001) and
decidua (p=0.002). HCV exposure results in increased NKG2D
(p=0.01) +CD158b in increased in control placenta compared to
cord blood (p=0.0004) and in HCV placenta compared to HCV
cord blood (p=0.02). CD158b is higher in HCV PBMC
compared to both HCV cord blood and control cord blood
(p,0.03). &Control placenta has lower NKp46 compared to
control cord blood (p=0.007) ¥ Control placenta is lower than
control cord blood (p=0.0002) and control decidua (p=0.005) P
Control placenta is lower in CD161 compared to control cord
blood (p=0.0006) and control decidua (p=0.02).
Found at: doi:10.1371/journal.pone.0012232.s003 (0.04 MB
DOC)
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